Single-photon emission computed tomography

NorthStar Medical Radioisotopes Provides Progress Update on RadioGenix® System, Reliable U.S. Molybdenum-99 (Mo-99) Supply, Production Expansion, and R&D Advancements

Retrieved on: 
Monday, March 16, 2020
Biotechnology, Medical devices, Health, Radiology, Pharmaceutical, Physical sciences, Natural sciences, Chemistry, Radiobiology, Radiopharmaceuticals, Radioactivity, Medical physics, MedWatch, Technetium, Radiopharmacology, Single-photon emission computed tomography, Radionuclide, the RadioGenix® System (Technetium Tc 99m Generator), NorthStar Medical Radioisotopes, LLC (NorthStar)

NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced a corporate update highlighting the continued commercial progress of its RadioGenix System (technetium Tc 99m generator).

Key Points: 
  • NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced a corporate update highlighting the continued commercial progress of its RadioGenix System (technetium Tc 99m generator).
  • Since becoming commercially available in 2018, NorthStar has provided RadioGenix System customers with reliable Mo-99 production and supply, despite ongoing industry supply shortages incurred with legacy, uranium-based production methods.
  • To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Medical Radioisotopes, LLC at 1-844-438-6659; or FDA at 1-800-332-1088 or www.fda.gov/medwatch .
  • Founded in 2006 and based in Beloit, Wis., NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC.

MIM Software Inc. Receives CE Mark Approval for Molecular Radiotherapy

Retrieved on: 
Thursday, March 12, 2020
Medical physics, Radiobiology, Branches of biology, Academic disciplines, Medicine, Single-photon emission computed tomography, MIM, Dosimetry, Medical imaging, Radiation therapy

CLEVELAND, March 12, 2020 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for its Molecular Radiotherapy product, MIM SurePlan MRT.

Key Points: 
  • CLEVELAND, March 12, 2020 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for its Molecular Radiotherapy product, MIM SurePlan MRT.
  • The CE Mark approval introduces a universal dosimetry solution for clinicians in Europe.
  • Other features of MIM SurePlan MRT include quantitative SPECT reconstruction and planar corrections, multi-tracer theranostics support, and dosimetry reporting tools.
  • Headquartered in Cleveland, OH, MIM Software is a privately held company with offices worldwide.

MIM Software Inc. Receives CE Mark Approval for Molecular Radiotherapy

Retrieved on: 
Thursday, March 12, 2020
Medical physics, Radiobiology, Branches of biology, Academic disciplines, Medicine, Single-photon emission computed tomography, MIM, Dosimetry, Medical imaging, Radiation therapy

CLEVELAND, March 12, 2020 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for its Molecular Radiotherapy product, MIM SurePlan MRT.

Key Points: 
  • CLEVELAND, March 12, 2020 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for its Molecular Radiotherapy product, MIM SurePlan MRT.
  • The CE Mark approval introduces a universal dosimetry solution for clinicians in Europe.
  • Other features of MIM SurePlan MRT include quantitative SPECT reconstruction and planar corrections, multi-tracer theranostics support, and dosimetry reporting tools.
  • Headquartered in Cleveland, OH, MIM Software is a privately held company with offices worldwide.

North America Hybrid Imaging Market - Drivers & Restraints to 2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 20, 2020
Medical devices, Health, Medical physics, Medicine, Neuroimaging, Branches of biology, Academic disciplines, Radiobiology, Nuclear medicine, Magnetic resonance imaging, Single-photon emission computed tomography, Medical imaging, Preclinical imaging

The "North America Hybrid Imaging Market (2019-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Hybrid Imaging Market (2019-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The considerable importance of a combined analysis of anatomic and molecular data to diagnose diseases is a key driver of the global market for hybrid imaging systems.
  • In addition to the advantages of hybrid imaging and its growing use in diagnostics, there is a significant opportunity for combination hybrid imaging PET or SPECT with MRI.
  • Accreditation of the site, technologist training, medical training and high processing costs among the underprivileged are the major constraints of the global market for hybrid imaging systems.

Global Nuclear Medicine Market is Projected to Reach USD 5.2 Billion by 2024 from an Estimated USD 4.1 Billion in 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 10, 2020
Energy, Health, Radiology, Pharmaceutical, Nuclear, Physical sciences, Natural sciences, Branches of biology, Medicinal radiochemistry, Medical physics, Radiopharmaceuticals, Radiobiology, Radiochemistry, Technetium-99m, Nuclear medicine, Single-photon emission computed tomography

The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period.

Key Points: 
  • The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period.
  • These factors are expected to hamper the growth of the nuclear medicine market during the forecast period.
  • In 2019, the Tc-99m segment is expected to command the largest share of the SPECT radiopharmaceuticals market.
  • The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the nuclear medicine market.

Nuclear Medicine/Radiopharmaceuticals Market Worth $5.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, January 27, 2020
Medicine, Physical sciences, Branches of biology, Medicinal radiochemistry, Medical physics, Neuroimaging, Radiobiology, Radiopharmaceuticals, Nuclear medicine, Single-photon emission computed tomography, Advanced Accelerator Applications, Preclinical SPECT

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.

Key Points: 
  • Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.
  • The diagnostic nuclear medicine segment is further categorized into SPECT and PET radiopharmaceuticals.
  • The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market in 2019.
  • Based on procedural volume assessment, the Nuclear Medicine Market is segmented into diagnostic and therapeutic procedures.

Nuclear Medicine/Radiopharmaceuticals Market Worth $5.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, January 27, 2020
Medicine, Physical sciences, Branches of biology, Medicinal radiochemistry, Medical physics, Neuroimaging, Radiobiology, Radiopharmaceuticals, Nuclear medicine, Single-photon emission computed tomography, Advanced Accelerator Applications, Preclinical SPECT

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.

Key Points: 
  • Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.
  • The diagnostic nuclear medicine segment is further categorized into SPECT and PET radiopharmaceuticals.
  • The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market in 2019.
  • Based on procedural volume assessment, the Nuclear Medicine Market is segmented into diagnostic and therapeutic procedures.

North American Nuclear Medicine/Radiopharmaceuticals Market Worth $2.7 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, January 24, 2020
Physical sciences, Medicine, Natural sciences, Medicinal radiochemistry, Medical physics, Radiobiology, Radiopharmaceuticals, Radiochemistry, Technetium-99m, Nuclear medicine, Single-photon emission computed tomography, Oncology

Based on application, the North American Radiopharmaceuticals Market is segmented into SPECT, PET, and therapeutic applications.

Key Points: 
  • Based on application, the North American Radiopharmaceuticals Market is segmented into SPECT, PET, and therapeutic applications.
  • The high growth of this segment can be attributed to the use of F-18 in PET oncology.
  • The large share of this segment can be attributed to the increasing use of Tc-99m in diagnostic nuclear medicine procedures.
  • Get 10% Customization on this Research Report:
    The North American Radiopharmaceuticals Market is segmented into the US and Canada, based on country.

North American Nuclear Medicine/Radiopharmaceuticals Market Worth $2.7 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, January 24, 2020
Physical sciences, Medicine, Natural sciences, Medicinal radiochemistry, Medical physics, Radiobiology, Radiopharmaceuticals, Radiochemistry, Technetium-99m, Nuclear medicine, Single-photon emission computed tomography, Oncology

Based on application, the North American Radiopharmaceuticals Market is segmented into SPECT, PET, and therapeutic applications.

Key Points: 
  • Based on application, the North American Radiopharmaceuticals Market is segmented into SPECT, PET, and therapeutic applications.
  • The high growth of this segment can be attributed to the use of F-18 in PET oncology.
  • The large share of this segment can be attributed to the increasing use of Tc-99m in diagnostic nuclear medicine procedures.
  • Get 10% Customization on this Research Report:
    The North American Radiopharmaceuticals Market is segmented into the US and Canada, based on country.

The global medical imaging market at a CAGR of about 5% during the forecast period

Retrieved on: 
Monday, September 23, 2019
Medical physics, Medicine, Medical imaging, Applied sciences, Branches of biology, Neuroimaging, Nuclear medicine, Medicinal radiochemistry, Positron emission tomography, Magnetic resonance imaging, Medical ultrasound, Single-photon emission computed tomography

This medical imaging market analysis considers sales from X-ray imaging, ultrasound imaging, MRI, CT scanner imaging, and SPECT/PET imaging products.

Key Points: 
  • This medical imaging market analysis considers sales from X-ray imaging, ultrasound imaging, MRI, CT scanner imaging, and SPECT/PET imaging products.
  • However, the high cost associated with medical imaging, product recalls, and stringent regulations associated withrelated to medical imaging equipment may hamper the growth of the medical imaging industry over the forecast period.
  • This will lead to the expansion of the global medical imaging market at a CAGR of about 5% during the forecast period.
  • It also enhances the features of medical imaging equipment, which drives the growth of the global medical imaging market.